Header Logo

Connection

Mark Pollack to Antidepressive Agents

Back to Details
This is a "connection" page, showing publications Mark Pollack has written about Antidepressive Agents.
Mark Pollack
Connection Strength
2.388
Antidepressive Agents
  1. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom. 2012; 81(2):87-97.
    View in: PubMed
    Score: 0.391
  2. Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: a pilot study of combination treatment with cognitive-behavior therapy vs sertraline alone. Behav Res Ther. 2003 Nov; 41(11):1271-6.
    View in: PubMed
    Score: 0.221
  3. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol. 2003 Sep; 17(3):276-82.
    View in: PubMed
    Score: 0.219
  4. Comorbidity, neurobiology, and pharmacotherapy of social anxiety disorder. J Clin Psychiatry. 2001; 62 Suppl 12:24-9.
    View in: PubMed
    Score: 0.182
  5. Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction. Ann Clin Psychiatry. 1997 Dec; 9(4):241-5.
    View in: PubMed
    Score: 0.147
  6. D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data. JAMA Psychiatry. 2017 05 01; 74(5):501-510.
    View in: PubMed
    Score: 0.141
  7. D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res. 2013 Oct; 47(10):1455-61.
    View in: PubMed
    Score: 0.108
  8. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. J Clin Psychiatry. 2012 Mar; 73(3):353-7.
    View in: PubMed
    Score: 0.095
  9. Preventing recurrent depression: long-term treatment for major depressive disorder. J Clin Psychiatry. 2007 Mar; 68(3):e06.
    View in: PubMed
    Score: 0.070
  10. Management of antidepressant-induced side effects: a practical guide for the clinician. J Clin Psychiatry. 1987 Jan; 48(1):3-8.
    View in: PubMed
    Score: 0.069
  11. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006 Mar; 67(3):381-5.
    View in: PubMed
    Score: 0.065
  12. The pharmacotherapy of panic disorder. J Clin Psychiatry. 2005; 66 Suppl 4:23-7.
    View in: PubMed
    Score: 0.060
  13. Comorbid anxiety and depression. J Clin Psychiatry. 2005; 66 Suppl 8:22-9.
    View in: PubMed
    Score: 0.060
  14. Unmet needs in the treatment of anxiety disorders. Psychopharmacol Bull. 2004; 38(1):31-7.
    View in: PubMed
    Score: 0.056
  15. Ropinirole for antidepressant-induced sexual dysfunction. Int Clin Psychopharmacol. 2002 Nov; 17(6):307-10.
    View in: PubMed
    Score: 0.052
  16. Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorder. J Affect Disord. 2002 May; 69(1-3):201-8.
    View in: PubMed
    Score: 0.050
  17. Panic disorder and response to sertraline: the effect of previous treatment with benzodiazepines. J Clin Psychopharmacol. 2001 Feb; 21(1):104-7.
    View in: PubMed
    Score: 0.046
  18. Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. J Clin Psychiatry. 2001; 62 Suppl 19:20-5.
    View in: PubMed
    Score: 0.045
  19. Group cognitive-behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: a clinical case series. Behav Res Ther. 1999 Aug; 37(8):763-70.
    View in: PubMed
    Score: 0.041
  20. Sertraline effects on dyspnea in patients with obstructive airways disease. Psychosomatics. 1998 Jan-Feb; 39(1):24-9.
    View in: PubMed
    Score: 0.037
  21. Long-term course and outcome of panic disorder. J Clin Psychiatry. 1997; 58 Suppl 2:57-60.
    View in: PubMed
    Score: 0.034
  22. Clinical issues in the long-term treatment of panic disorder. J Clin Psychiatry. 1996; 57 Suppl 10:44-8; discussion 49-50.
    View in: PubMed
    Score: 0.032
  23. Current status of pharmacotherapy for PTSD: an effect size analysis of controlled studies. Depress Anxiety. 1996-1997; 4(5):240-2.
    View in: PubMed
    Score: 0.032
  24. The longitudinal course and outcome of panic disorder. Psychiatr Clin North Am. 1995 Dec; 18(4):785-801.
    View in: PubMed
    Score: 0.032
  25. Genitourinary and sexual adverse effects of psychotropic medication. Int J Psychiatry Med. 1992; 22(4):305-27.
    View in: PubMed
    Score: 0.024
  26. Neuroendocrine effects of S-adenosyl-L-methionine, a novel putative antidepressant. J Psychiatr Res. 1990; 24(2):177-84.
    View in: PubMed
    Score: 0.021
  27. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry. 1989 Dec; 50(12):447-9.
    View in: PubMed
    Score: 0.021
  28. Orthostatic hypotension and antidepressant pharmacotherapy. Psychopharmacol Bull. 1987; 23(1):182-6.
    View in: PubMed
    Score: 0.017
  29. Anxiety in patients with pulmonary disease: comorbidity and treatment. Semin Clin Neuropsychiatry. 1999 Apr; 4(2):84-97.
    View in: PubMed
    Score: 0.010
  30. Dizziness and panic disorder: a review of the association between vestibular dysfunction and anxiety. Ann Clin Psychiatry. 1998 Jun; 10(2):75-80.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.